top of page
POLEN
Biomarker changes associated to short exposure to olaparib as potential predictors in Endometrial Carcinoma
CLINICAL TRIAL DETAILS
A PREOPERATIVE “WINDOW-OPPORTUNITY”, MULTICENTER, PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO EVALUATE THE INHIBITORY EFFECTS OF SINGLE AGENT AZD2281 (OLAPARIB), IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA. THE PRIMARY OBJECTIVE OF THIS STUDY IS TO IDENTIFY, IN HUMAN TUMOUR SAMPLES, BIOMARKER CHANGES ASSOCIATED TO SHORT EXPOSURE TO AZD2281 AS POTENTIAL PREDICTORS OF ACTIVITY IN ENDOMETRIAL CARCINOMA (EC). THIS IS AN EXPLORATORY STUDY WITH A BIOLOGICAL PRIMARY ENDPOINT. CLINICAL EFFICACY OR SAFETY ARE NOT A PRIMARY OBJECTIVE OF THE STUDY.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ENDOMETRIAL
9
36
0
Spain
Closing
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
Instituto Valenciano de Oncología (IVO) (Spain)
Hospital Clínic i Provincial de Barcelona (Spain)
Hospital Clínico San Carlos (Spain)
Hospital Universitario Reina Sofía (Spain)
Hospital Universitario Ramón y Cajal (Spain)
Complejo Hospitalario Universitario de Santiago (CHUS) (Spain)
Hospital de Granollers (Spain)
Complejo Hospitalario Universitario A Coruña (CHUAC) (Spain)
Hospital Álvaro Cunqueiro (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page